1.31
price down icon7.09%   -0.10
after-market アフターアワーズ: 1.28 -0.03 -2.29%
loading
前日終値:
$1.41
開ける:
$1.38
24時間の取引高:
248.73K
Relative Volume:
0.52
時価総額:
$25.53M
収益:
-
当期純損益:
$-40.94M
株価収益率:
-0.3411
EPS:
-3.84
ネットキャッシュフロー:
$-22.97M
1週間 パフォーマンス:
-20.61%
1か月 パフォーマンス:
-21.08%
6か月 パフォーマンス:
-84.42%
1年 パフォーマンス:
-88.13%
1日の値動き範囲:
Value
$1.28
$1.38
1週間の範囲:
Value
$1.28
$1.70
52週間の値動き範囲:
Value
$1.28
$20.00

Annovis Bio Inc Stock (ANVS) Company Profile

Name
名前
Annovis Bio Inc
Name
セクター
Healthcare (1162)
Name
電話
484-875-3192
Name
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Name
職員
6
Name
Twitter
Name
次回の収益日
2024-12-11
Name
最新のSEC提出書
Name
ANVS's Discussions on Twitter

ANVS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ANVS
Annovis Bio Inc
1.31 25.53M 0 -40.94M -22.97M -3.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-10 ダウングレード D. Boral Capital Buy → Hold
2024-10-25 アップグレード Maxim Group Hold → Buy
2023-12-29 開始されました Canaccord Genuity Buy
2021-07-07 繰り返されました Maxim Group Buy

Annovis Bio Inc (ANVS) 最新ニュース

pulisher
Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025
pulisher
Mar 30, 2025

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN

Mar 30, 2025
pulisher
Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire

Mar 26, 2025
pulisher
Mar 25, 2025

Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews

Mar 25, 2025
pulisher
Mar 25, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025
pulisher
Mar 25, 2025

Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Game-Changing Phase 3 Results: Annovis Reveals Dual Breakthrough in Parkinson's and Alzheimer's Treatment - Stock Titan

Mar 25, 2025
pulisher
Mar 21, 2025

Annovis Bio Inc. (ANVS) reports earnings - Quartz

Mar 21, 2025
pulisher
Mar 21, 2025

Annovis Bio, Inc. SEC 10-K Report - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times

Mar 21, 2025
pulisher
Mar 21, 2025

Annovis Bio Inc. Reports Corporate Updates and Financial Results for Fourth Quarter and Full Year 2024 - Nasdaq

Mar 21, 2025
pulisher
Mar 11, 2025

Annovis Bio stock hits 52-week low at $1.55 amid sharp decline - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Revolutionary Parkinson's Treatment: Annovis Unveils Phase III Data for Multi-Target Drug - StockTitan

Mar 11, 2025
pulisher
Mar 03, 2025

LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.

Mar 03, 2025
pulisher
Mar 03, 2025

Atria Wealth Solutions Inc. Purchases Shares of 13,002 Annovis Bio, Inc. (NYSE:ANVS) - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

Annovis Bio stock hits 52-week low at $1.72 amid market challenges - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

ANVS ALERTLabaton Sucharow Announces the Filing of a Securities Class Action Against Annovis Bio, Inc.; Investors Encouraged to Contact the Firm Before October 18 - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Annovis Bio stock hits 52-week low at $1.72 amid market challenges By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 20, 2025

Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN

Feb 20, 2025
pulisher
Feb 20, 2025

Annovis Bio stock hits 52-week low at $2.42 amid market challenges By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com Australia

Feb 20, 2025
pulisher
Feb 20, 2025

Annovis to Host Patients’ Live Forum on February 27, 2025 - GlobeNewswire

Feb 20, 2025
pulisher
Feb 19, 2025

Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow

Feb 19, 2025
pulisher
Feb 19, 2025

Inside Annovis's Groundbreaking Alzheimer's Trial: CEO Opens Direct Dialogue With Patients - StockTitan

Feb 19, 2025
pulisher
Feb 16, 2025

Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN

Feb 16, 2025

Annovis Bio Inc (ANVS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
大文字化:     |  ボリューム (24 時間):